Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference
November 16 2020 - 4:05PM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve, today announced that Fred Guerard, PharmD, Chief Executive
Officer of Graybug Vision, will participate in a fireside chat in
advance of the virtual Piper Sandler Healthcare Conference, being
held December 1-3, 2020.
A recording of the fireside chat will be accessible beginning
November 23, 2020 by visiting IR Events & Presentations in the
Investors and Media section of the company’s website at
https://investors.graybug.vision/news-events/events-presentations.
The recording will be available on the Graybug website for 14 days
following the conference.
About Graybug Vision
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for the treatment of diseases
of the retina and optic nerve. The company’s proprietary ocular
delivery technologies are designed to maintain effective drug
levels in ocular tissue for six months and potentially longer,
improving disease management, reducing healthcare burdens and
ultimately delivering better clinical outcomes. Graybug’s lead
product candidate, GB-102, a microparticle depot formulation of the
pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib
malate, targeting a six-month or longer dosing regimen, inhibits
multiple neovascular pathways for the intravitreal treatment of
retinal diseases, including wet age-related macular degeneration.
Graybug is also using its proprietary technologies to develop
GB-401, an injectable depot formulation of a beta-adrenergic
blocker prodrug, for primary open-angle glaucoma, with a dosing
regimen of once every six months or longer, and GB-103, a
longer-acting version of GB-102, designed to maintain therapeutic
drug levels in the retinal tissue for 12 months with a single
injection. Founded in 2011 on the basis of technology licensed from
the Johns Hopkins University School of Medicine, Graybug is
headquartered in Redwood City, California. For more information,
please visit www.graybug.vision.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Apr 2023 to Apr 2024